West Pharmaceutical Services (WST) Other Non-Current Liabilities (2009 - 2026)

West Pharmaceutical Services has disclosed Other Non-Current Liabilities across 18 years of filings, most recently posting $87.6 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $87.6 million, up 33.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $87.6 million (up 33.33% YoY), and the FY2025 annual result was $75.2 million, up 20.9% from the prior year.
• Other Non-Current Liabilities came in at $87.6 million for Q1 2026 at West Pharmaceutical Services, up from $75.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $87.6 million in Q1 2026 to a low of $33.9 million in Q3 2022.
• The 5-year median for Other Non-Current Liabilities is $58.5 million (2023), against an average of $59.2 million.
• Across the five-year window, Other Non-Current Liabilities soared 62.54% in 2023 and rose 3.76% in 2024, its largest moves.
• West Pharmaceutical Services' Other Non-Current Liabilities stood at $51.6 million in 2022, then rose by 13.37% to $58.5 million in 2023, then advanced by 6.32% to $62.2 million in 2024, then grew by 20.9% to $75.2 million in 2025, then rose by 16.49% to $87.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $87.6 million (Q1 2026), $75.2 million (Q4 2025), and $75.3 million (Q3 2025), per Business Quant data.